Minimal Residual Disease Monitoring Using a 3′ALK Universal Probe Assay in ALK-Positive Anaplastic Large-Cell Lymphoma
Autor: | Anne Pradines, Laurence Lamant, Emeline Sarot, Laurence Brugières, David Sibon, David Grand, Cathy Quelen, Pierre Brousset, Camille Laurent |
---|---|
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
Alternative methods ALK-Positive Anaplastic Large Cell Lymphoma business.industry medicine.disease Minimal residual disease Pathology and Forensic Medicine Lymphoma 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Real-time polymerase chain reaction medicine.anatomical_structure Fusion transcript hemic and lymphatic diseases 030220 oncology & carcinogenesis Cancer research medicine Molecular Medicine Bone marrow Liquid biopsy business |
Zdroj: | The Journal of Molecular Diagnostics. 23:131-139 |
ISSN: | 1525-1578 |
Popis: | In ALK-positive anaplastic large-cell lymphomas, positive qualitative PCR for NPM1–anaplastic lymphoma kinase (ALK) in peripheral blood and/or bone marrow at diagnosis and during treatment are associated with a higher risk of treatment failure. Real-time quantitative PCR allows identification of very high risk patients. However, this latter technique initially designed for patients with lymphomas carrying the most frequent NPM1-ALK translocation necessitates calibration curves, limiting interlaboratory reproducibility. An ALK universal quantitative PCR based on 3′ALK transcript amplification was designed to allow the detection of all ALK fusion transcripts. The absolute concordance of 3′ALK quantitative PCR results were validated with the routine NPM1-ALK qualitative and quantitative PCR on 46 samples. The universality of ALK fusion transcript detection also was validated on TPM3-, ALO17-, and ATIC-ALK–positive samples, and the EML4-ALK–positive cell line. Digital droplet PCR using the 3′ALK universal probe showed highly concordant results with 3′ALK universal quantitative PCR. A major benefit of digital droplet PCR is a reduced experimental set-up compared with quantitative PCR, without generation of standard curves, leading to a reliable protocol for multilaboratory validation in multicenter clinical trials essential for this rare pathology. Our ALK universal method could be used for the screening of ALK fusion transcripts in liquid biopsy specimens of other ALK-positive tumors, including non–small cell lung carcinomas. |
Databáze: | OpenAIRE |
Externí odkaz: |